559
Participants
Start Date
December 31, 2015
Primary Completion Date
March 23, 2021
Study Completion Date
May 23, 2021
Docetaxel + Plinabulin (DP)
Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Docetaxel (D)
Docetaxel 75 mg/m2 IV
Blacktown Cancer Centre, Blacktown
Gosford Hospital, Gosford
Border Medical Oncology Research Unit, East Albury
Epworth Hospital, Richmond
Peninsula and South East Oncology, Melbourne
Adult Mater Hospital, South Brisbane
Perth Oncology/Mount Hospital, Perth
St John of God Hospital, Subiaco, Subiaco
Fiona Stanley Hospital, Murdoch
Allegheny Health Network, Pittsburgh
Wake Forest Baptist Health, Winston-Salem
Peachtree Hematoloy-Oncology Consultants, PC, Atlanta
Hattiesburg Clinic Hematology/Oncology, Hattiesburg
University of Louisville-Brown Cancer Center, Louisville
Toledo Cancer Center, Toledo
University of Cincinnati, Cincinnati
Henry Ford Hospital, Detroit
Michigan Center of Medical Research, Farmington Hills
Orchard Healthcare Research Inc., Skokie
Carle Cancer Center, Urbana
Cookeville Regional Medical Center Cancer Center, Cookeville
Central Care Cancer Center, Bolivar
Memorial Health Care System, Colorado Springs
Ironwood Cancer & Research Centers, Chandler
Innovative Clinical Research Institute, Whittier
Pacific Cancer Medical Center, Inc., Anaheim
Jilin Province Cancer Hospital, Changchun
Cancer Hospital Chinese Academy of Medical Science, Beijing
Beijing Cancer Hospital, Beijing
The PLA General Hospital, Beijing
Liaoning Cancer Hospital & Institute, Shenyang
Affiliated Cancer Hospital of Harbin Medical Unive, Harbin
Shanghai Chest Hospital, Shanghai Jiaotong Univers, Shanghai
The Fifth People's Hospital of Shanghai, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangyin People's Hospital, Jiangyin
Nantong Tumor Hospital, Nantong
Anhui Provincial Hospital, Hefei
Shandong Cancer Hospital, Jinan
Yantai Yuhuangding Hospital, Yantai
527-Linyi Cancer Hospital, Linyi
Tianjin People's Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University, Hanzhou
Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Jiangxi Provincial Tumor Hospital, Nanchang
The First Affiliated Hospital of Xiamen University, Xiamen
Zhongshan Hospital Xiamen University, Xiamen
The Second Xiangya Hospital of Central South Unive, Changsha
Henan Cancer Hospital, Zhengzhou
Guizhou Provincial Hospital, Guiyang
West China Hospital of Sichuan University, Chengdu
The First Affiliated Hospital of Xi'an Jiaotong U, Xi'an
Affiliated Tumor Hospital of Xinjiang Medical Univ, Ürümqi
Cancer Center of Central Connecticut, Plainville
Kansas University Medical Center, Westwood
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
BeyondSpring Pharmaceuticals Inc.
INDUSTRY